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Arylamine N-acetyltransferases (NATs) are drug and xenobiotic metabolizing enzymes that catalyze the
N-acetylation of arylamines and hydrazines and the O-acetylation of N-hydroxy-arylamines. Recently,
studies report that human NAT1 and mouse Nat2 hydrolyze acetyl-coenzyme A (AcCoA) into acetate and
coenzyme A in a folate-dependent fashion, a previously unknown function. In this study, our goal was to
conﬁrm these ﬁndings and determine the apparent Michaelis–Menten kinetic constants (Vmax and Km) of
the folate-dependent AcCoA hydrolysis for human NAT1/NAT2, and the rodent analogs rat Nat1/Nat2,
mouse Nat1/Nat2, and hamster Nat1/Nat2. We also compared apparent Vmax values for AcCoA hydrolysis
and N-acetylation of the substrate para-aminobenzoic acid (PABA). Human NAT1 and its rodent analogs
rat Nat2, mouse Nat2 and hamster Nat2 catalyzed AcCoA hydrolysis in a folate-dependent manner. Rates
of AcCoA hydrolysis were between 0.25–1% of the rates for N-acetylation of PABA catalyzed by human
NAT1 and its rodent orthologs. In contrast to human NAT1, human NAT2 and its rodent analogs rat Nat1,
mouse Nat1, and hamster Nat1 did not hydrolyze AcCoA in a folate-dependent manner. These results are
consistent with the possibility that human NAT1 and its rodent analogs regulate endogenous AcCoA
levels.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Arylamine N-acetyltransferases (NATs) are phase II cytosolic
isoenzymes responsible for the metabolism of arylamine and
N-hydroxylarylamine drugs and xenobiotics [1]. The isoenzymes
catalyze the transfer of the acetyl group from acetyl-coenzyme A
(AcCoA) to the exocyclic amine of an arylamine (N-acetylation) or
the hydroxylated amine of an N-hydroxylated arylamine (O-acet-
ylation) [2–4]. NATs are able to bioactivate procarcinogens like
4-aminobiphenyl (ABP), a component of cigarette smoke [1]. Also,
NATs metabolize various pharmaceutical drugs, such as the anti-
bacterial (sulfonamides), antitubercular (isoniazid), and antiar-
rhythmic (procainamide) drugs [5–7]. Understanding N-acetyl-
transferase function, expression, and regulation aids in predicting
individual drug toxicities or individual tissue-speciﬁc cancer sus-
ceptibilities associated with environmental and/or occupational
carcinogen exposures.
The human genome codes for two functional NATs, NAT1 andB.V. This is an open access article u
earch – Room 303, University
ncock Street, Louisville, KY
Stepp),
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edu (D.W. Hein).NAT2, that are located on the short arm of chromosome 8 [8].
Human NAT1 is expressed in nearly all human tissues [9,10]. Hu-
man NAT2 is primarily expressed in the liver and gut [11]. The two
NATs differ from each other in substrate speciﬁcity, structural
stability, and tissue speciﬁc expression [12]. There is also an in-
active NAT pseudogene known as NATP [13].
Amino acid residues at positions 125, 127, and 129 determine
substrate speciﬁcity of the 290 amino acid NAT protein [14]. When
comparing the amino acids at the three mentioned positions in rat
Nat2 and mouse Nat2 with human NAT1, they share all three
amino acids (Phe125, Arg127, and Tyr129). However hamster Nat2
shares only two out of three amino acids (Phe125 and Arg127)
with human NAT1. This shared amino acid similarity suggests that
these NATs will have similar substrate speciﬁcity. The C-terminus
undecapeptide tail of the NATs controls the hydrolysis of AcCoA
[15]. The C-terminus undecapeptide tail of rat, mouse, and ham-
ster Nat2 and human NAT1 share 100% identical amino acids
suggesting they are orthologs. Conversely rodent Nat1 and human
NAT2 do not align as similarly as rodent Nat2 and human NAT1.
Only rat Nat1 (Tyr125, Ser127, and Tyr129) shares a single similar
amino acid for the active site in human NAT2 (Ser125, Ser127,
Ser129). The mouse and hamster Nat1 (Tyr125, Gly127, Tyr129)
share the same active site amino acids with each other, but do not
share any similarity to human NAT2. The C-terminus undecapep-
tide tails for rodent Nat1 and human NAT2 also do not have muchnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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[8,16].
N-acetyltransferases have been shown to play a role in devel-
opment [17]. It has been proposed that human NAT1 inﬂuences
folate homeostasis and thus, affects the neural tube development
[18]. Human NAT1 acetylates the folate catabolite, para-amino-
benzoyl-1-glutamate [19]. Recent studies report that human NAT1
and mouse Nat2 hydrolyze AcCoA into acetate and coenzyme A in
a folate-dependent fashion [20], a previously unknown function
(Fig. 1). In this study, our goal was to conﬁrm these ﬁndings and
determine the apparent Michaelis–Menten kinetic constants (Vmax
and Km) of the folate-dependent AcCoA hydrolysis for human
NAT1/NAT2 and the rodent analogs rat Nat1/Nat2, mouse Nat1/
Nat2, and hamster Nat1/Nat2. We also compared apparent Vmax
values for AcCoA hydrolysis to N-acetylation of the substrate para-
aminobenzoic acid (PABA).Fig. 1. AcCoA-dependent N-acetylation of arylamine substrate (A) and folate-de-
pendent hydrolysis of AcCoA in absence of arylamine acceptor substrate (B).2. Methods and materials
2.1. Arylamine N-acetyltransferases recombinant expression
Methods for the cloning and expression of the recombinant
human and rodent arylamine N-acetyltransferases have been re-
ported in previous publications from our laboratory for human
[21], rat [22], mouse [23], and hamster [24,25]. In brief, JM105
Escherichia coli strain was transformed with NAT containing
pkk223-3 plasmid. The transformed JM105 E. coli was picked as a
single colony and cultured overnight in 50 ml LB medium con-
taining ampicillin (100 μg/ml) at 37 °C. The following day, 4 ml of
the overnight culture was added to 200 ml fresh sterile LB media
containing ampicillin (100 μg/ml) and grown until the optical
density (OD600 nm) reached 0.4–0.6. Expression of N-acetyl-
transferases was induced by addition of isopropyl β-D-thioga-
lactopyranoside (ﬁnal concentration 1 mM) for 3 h. Cells were
harvested by centrifugation at 5000g for 10 min at 4 °C and the
cell pellet was suspended in 10 ml of ice-cold 20 mM NaPO4, 1 mM
dithiothreitol, 1 mM EDTA, 0.2% triton-x-100, 100 mM phe-
nylmethylsulfonyl ﬂuoride, 1 mM pepstatin A, and 1 mg/mL aproti-
nin. The solution was sonicated on ice 6 times for 30 s. The lysate
was centrifuged at 15,000g for 20 min at 4 °C. Aliquots of super-
natant were stored at 80 °C until use.
2.2. PABA N-acetylation assays
PABA N-acetylation assays were done as previously described
[26]. Brieﬂy, recombinant lysate was added to a mixture of PABA
(Sigma Aldrich) and AcCoA (Amersham Biosciences), whose ﬁnal
concentrations in the reaction were 150 μM and 400 μM, respec-
tively. The mixture was incubated at 37 °C for 10 min, after which
the reaction was quenched with 1/10 volume of 1 M acetic acid.
Precipitated proteins were removed by centrifugation. Super-
natants were injected on a C18 column and reaction substrates and
products separated and quantitated using Beckman System Gold
high performance liquid chromatography (HPLC).
2.3. AcCoA hydrolysis assays
Recombinant lysates were added to folate (Sigma-Aldrich) and
AcCoA. Initial reactions were carried out at 37 °C with ﬁxed con-
centrations of folate (500 μM) and AcCoA (400 μM) to determine
appropriate enzyme lysate dilutions for subsequent reactions.
Next, reactions were performed to determine Michaelis–Menten
constants for AcCoA. Reactions were done at 500 μM folate and
varying AcCoA concentrations from 0 μM to 400 μM. The third set
of reactions was done with AcCoA ﬁxed at 400 μM for mouse andhamster and 200 μM for human and rat with folate concentrations
varied between 0 and 400 mM. Control reactions were done with
the same enzyme and AcCoA concentrations but no folate. The
amounts of CoA produced in the minus folate reactions were
subtracted from reactions containing folate to determine folate-
dependent hydrolysis. The reaction mixtures were incubated at
37 °C for 10 min, after which the reactions were quenched by
adding 1/10 volume of perchloric acid (15% w/v). The precipitated
protein was removed by centrifugation and the supernatant was
injected onto a C18 reverse-phase HPLC column (250 mm4 mm;
5 μM pore size). Reactants and products were separated and
quantitated by HPLC. Separation of CoA, acetyl CoA, and folate was
achieved using a linear gradient of 100% 55 mM sodium phosphate
(NaH2PO4) pH 4.0: 0% methanol to 0% 55 mM sodium phosphate
pH 4.0: 100% methanol over 20 min and was quantitated by ab-
sorbance at 260 nm. The limit of detection for CoA was
0.05 nmoles/min/mg of protein.
2.4. Statistics
All the data are shown as mean7SEM from three separate
determinations. The Michaelis–Menten constants (Km and Vmax)
were determined by nonlinear regression of the Michaelis–Men-
ten equation (GraphPad Software, Inc, San Diego, CA).3. Results
3.1. Michaelis–Menten saturation curves for AcCoA hydrolysis
Hydrolysis with (Fig. 2, solid line) or without (Fig. 2, dash line)
the addition of folate (both in the absence of any arylamine NAT1
substrate) were determined for human NAT1 and rodent Nat2.
Some hydrolysis of AcCoA to form CoA was observed in the ab-
sence of folate (Fig. 2). Since this folate-independent hydrolysis of
AcCoA to form CoA was also observed in bacterial lysates from
recombinantly expressed vector controls, this folate-independent
hydrolysis of AcCoA was subtracted from folate-dependent AcCoA
hydrolysis rates in the subsequent measurements described be-
low.
Fig. 2. Michaelis–Menten saturation curves for AcCoA hydrolysis with (circles with solid line) or without (squares with dashed line) 500 μM folate (with no arylamine
substrate present). Hydrolysis activity was catalyzed by human NAT1 (A) and rodent Nat2s (B–D). Data points represent results from three separate determinations with
mean7SEM.
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human NAT1 and NAT2
For human NAT1 the apparent Vmax and Km values determined
for AcCoA in the AcCoA hydrolysis reaction were 111713 nmoles/
min/mg protein and 54.3720.5 μM, respectively (Fig. 3A, solid
line). For human NAT1 the apparent Vmax and Km values de-
termined for folate in the AcCoA hydrolysis reaction were
200718 nmoles/min/mg protein and 85.2721.5 μM, respectively
(Fig. 3A, dash line). Initial rate constant for PABA N-acetylation
activity for recombinant human NAT1 was 20,30071720 nmoles/
min/mg protein. Human NAT2 AcCoA hydrolysis activity was be-
low the level of detection (0.05 nmoles/min/mg of protein).
3.3. AcCoA hydrolysis and N-acetylation activities of recombinant rat
Nat1 and Nat2
For rat Nat2 the apparent Vmax and Km values determined for
AcCoA in the AcCoA hydrolysis reaction were 13.572.6 nmoles/
min/mg protein and 126760 μM, respectively (Fig. 3B, solid line).
For rat Nat2 the apparent Vmax and Km values determined for folate
in the AcCoA hydrolysis reaction were 7.6170.78 nmoles/min/mg
protein and 29.5714.0 μM, respectively (Fig. 3B, dash line). Initial
rate constant for PABA N-acetylation activity for recombinant rat
Nat2 was 30307274 nmoles/min/mg protein. Rat Nat1 AcCoA
hydrolysis activity was below the level of detection (0.05 nmoles/
min/mg of protein).
3.4. AcCoA hydrolysis and N-acetylation activities of recombinantmouse Nat1 and Nat2
For mouse Nat2 the apparent Vmax and Km values determined
for AcCoA in the AcCoA hydrolysis reaction were 13079 nmoles/
min/mg protein and 88.3718.3 μM, respectively (Fig. 3C, solid
line). For mouse Nat2 the apparent Vmax and Km values determined
for folate in the AcCoA hydrolysis reaction were 120714 nmoles/
min/mg protein and 77.1727.9 μM, respectively (Fig. 3C, dash
line). Initial rate constant for PABA N-acetylation activity for re-
combinant mouse Nat2 was 32,60071170 nmoles/min/mg pro-
tein. Mouse Nat1 AcCoA hydrolysis activity was below the level of
detection (0.05 nmoles/min/mg of protein).
3.5. AcCoA hydrolysis and N-acetylation activities of recombinant
hamster Nat1 and Nat2
For hamster Nat2 the apparent Vmax and Km values determined
for AcCoA in the AcCoA hydrolysis reaction were 200713 nmoles/
min/mg protein and 164724 μM, respectively (Fig. 3D, solid line).
For hamster Nat2 the apparent Vmax and Km values determined for
folate in the AcCoA hydrolysis reaction were 18675 nmoles/min/
mg protein and 94.076.5 μM, respectively (Fig. 3D, dash line).
Initial rate constants for PABA N-acetylation activity for re-
combinant hamster Nat2 was 20,70071350 nmoles/min/mg pro-
tein. Hamster Nat1 AcCoA hydrolysis activity was below the level
of detection (0.05 nmoles/min/mg of protein).
3.6. Comparison of AcCoA hydrolysis to PABA N-acetylation
Human NAT1 and rodent Nat2 lysates were able to N-acetylate
Fig. 3. Michaelis–Menten saturation curves with various concentrations of AcCoA (solid line) and folate (dashed line) for human NAT1 (A), rat Nat2 (B) mouse Nat2 (C) and
hamster Nat2 (D). Hydrolysis activity in nmol/min/mg protein is plotted on the ordinate versus substrate concentration on the abscissae. Folate concentration was ﬁxed at
500 mM for AcCoA Vmax and Km determinations. AcCoA concentration was ﬁxed at 200 μM for human NAT1 and rat Nat2 and 400 μM for mouse Nat2 and hamster Nat2 folate
apparent Vmax and Km determinations. Data points represent mean7SEM from three separate determinations.
Table 1
Comparisons of PABA N-acetylation and AcCoA hydrolysis by recombinant human NAT1 and rodent Nat2 enzymes.
AcCoA hydrolysis Apparent hydrolytic Vmax
Apparent Vmax(nmol/min/mg) PABA N-acetylation(nmol/min/mg) /PABA acetylation
AcCoA Folate AcCoA (%) Folate (%)
Human NAT1 111 713 200 718 20300 71720 0.547 0.985
Rat Nat2 13.5 72.6 7.61 70.78 3030 7274 0.446 0.251
Mouse Nat2 130 79 120 714 32600 71170 0.399 0.368
Hamster Nat2 200 713 186 75 20700 71350 0.966 0.899
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human NAT1 and rodent Nat2 lysates were 0.25–1% relative to the
initial rate constant for PABA N-acetylation catalyzed by the same
enzyme (Table 1).4. Discussion
Folate is a water soluble B vitamin found in various foods (leafy
green vegetables, organ meat, etc.), and folic acid is commonly
used to fortify foods. Commercial fortiﬁcation was mandated to
prevent developmental defects in early fetal development. How-
ever, of growing interest and experimentation is whether folate
levels in the body and folic acid supplementation affects tumor
induction and progression [27].
Our study has conﬁrmed that human NAT1 and the rodent
ortholog mouse Nat2 are capable of catalyzing AcCoA hydrolysis inthe presence of folate but absence of xenobiotic substrate (e.g.
PABA) as shown by Laurieri et al. [20]. This study also conﬁrmed
that folate is not consumed in the hydrolysis reaction and that
human NAT2 and mouse Nat1 do not perform this reaction to any
signiﬁcant degree. In addition, we have shown that hamster and
rat Nat2 enzymes also catalyze this AcCoA hydrolysis, while the
hamster and rat Nat1 have no detectable AcCoA hydrolysis activity.
A new methodology was developed in the study to measure the
level of CoA, AcCoA, and folate by HPLC. We determined the Mi-
chaelis–Menten kinetic constants (Vmax and Km) for both AcCoA
and folate using human NAT1 as well as three rodent Nat2
enzymes.
Human NAT1 had Vmax and Km values similar to hamster and
mouse Nat2 but different from rat Nat2 for both varying AcCoA
and folate concentrations. Also, when comparing Vmax and Km
values for folate and AcCoA curves among the individual human
and rodent enzymes they also appeared to be surprisingly similar.
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PABA N-acetylation activity for the same enzyme. The total body
content of folate is estimated to be 10–30 mg; about half of this
amount is stored in the liver and the remainder in blood and body
tissues [28]. Erythrocyte folate concentrations in the USA and
Canada recently were reported from 0.5 to 2.5 nmol/L but varied
with assay method, diet and supplementation. Modest correla-
tions recently were reported between plasma and breast folate
concentrations [29] suggesting that plasma levels may not predict
concentrations of folate in various tissues. Future studies with
NAT2 knock out mice [18] or congenic Nat2 rapid and slow acet-
ylator rats [30] may help to determine whether changes in level of
human NAT1 (rodent Nat2) expression affect AcCoA levels in vivo
and thus possibly affect cellular metabolism.
Endogenous human NAT1 expression/activity is frequently ob-
served in human cells [31]. Overexpressing NAT1 in non-trans-
formed breast epithelial cells, HB4a, gave the cells increased
growth and survival [32]. The use of a lentiviral shRNA expression
system for NAT1 knockdown in a human breast cancer cell line,
MDA-MB-231, caused a decrease in cell invasion [33]. Similar
knockdown in a colon cancer cell line, HT-29, resulted in a de-
crease in cell growth, anchorage independent cell growth, as well
as cell invasion [34]. A small molecule NAT1 inhibitor, Rhod-o-hp,
showed that NAT1 inhibition in MDA-MB-231 cells decreased cell
proliferation, inhibited anchorage-independent growth, and re-
duced the invasiveness of the cell [33]. Microarray data showed
increased NAT1 expression was clustered with positive estrogen
receptor expression [35,36]. This correlation between positive es-
trogen receptor status and NAT1 was reafﬁrmed by additional
microarray studies [37–40]. Also, elevated NAT1 mRNA level is
associated with more invasive breast cancers [41]. All these lines of
evidence suggest an association between NAT1 and cancer; how-
ever, the endogenous mechanisms of NAT1 in carcinogenesis re-
main unclear. Folate-dependent hydrolysis of AcCoA catalyzed by
NAT1 suggests a possible endogenous mechanism for its involve-
ment in carcinogenesis.
In summary, our results are consistent with the possibility that
human NAT1 and its rodent Nat2 orthologs regulate endogenous
AcCoA levels in a folate-dependent reaction. The results suggest
associations of human NAT1 activity with disease or tumor pro-
gression may be related to regulation of AcCoA. Further studies are
needed to explore this hypothesis.Funding information
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